In tenosynovitis, we further hypothesize that PDGF-AB’s early peak (8 h) correlates with acute symptom relief, while VEGF’s late peak (Day 14) supports structural improvements in sheath vascularization, with PRP outperforming saline in pain, function, and tendon thickness at 3 months. The gene discussed is VEGFA; the disease is tenosynovitis.